APA (7th ed.) Citation

Y, W., G, G., X, W., Y, Z., & J, Y. (2023, May). UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. Drug Design, Development and Therapy.

Chicago Style (17th ed.) Citation

Y, Wang, Gao G, Wei X, Zhang Y, and Yu J. "UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway." Drug Design, Development and Therapy May. 2023.

MLA (9th ed.) Citation

Y, Wang, et al. "UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway." Drug Design, Development and Therapy, May. 2023.